CARMAT Completes Enrolment in the EFICAS Clinical Study and Receives Approval From French Authorities for 21 Additional Aeson® Implants, While Awaiting Potential Reimbursement of the Device in France
PARIS--(BUSINESS WIRE)--Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the completion of enrolment of the 52 patients planned in the EFICAS study, and the approval from the French authorities to perform 21 additional Aeson® implants, while awaiting potential reimbursement of the device in France.
Stéphane Piat, Chief Executive Officer of CARMA, commented: 'The very strong momentum in the EFICAS study, which enrolment is now complete, reflects the quality and performance of our Aeson® artificial heart and its ability to address the unmet need expressed by healthcare professionals and patients. I am convinced that this study paves the way for strong sales development in Europe and beyond - particularly once its results will have been published, hopefully as soon as end of 2025.
I am also very pleased that, by approving 21 additional implants, the French authorities enable patients in France to continue benefitting from our therapy beyond the EFICAS study. This is a strong sign of confidence in Aeson® artificial heart.
Given the study design, we anticipate to be in a position to file for Aeson®'s reimbursement in France early next year, which could lead to coverage of our artificial heart by the French Social Security system during 2026.
The EFICAS study is also important given our strategy to access the U.S. market, which we are expecting to achieve in 2028.
I would like to thank all patients and healthcare professionals, as well as our teams for their contribution to this important step in Aeson®'s development.'
Enrolment completed in the EFICAS study
Initiated in November 2022, the EFICAS clinical study is the largest ever one conducted by CARMAT. It involves 52 patients eligible for a heart transplant and is carried out across 10 hospitals in France 1.
The primary endpoint of EFICAS is patient survival at 6 months post-Aeson® implant, without disabling stroke, or a successful heart transplant within that period.
EFICAS is key to support Aeson®'s commercial rollout in Europe 2 (through 'evidence-based medicine'), and secure its reimbursement in France, and is also expected to contribute to securing the Pre-Market Approval (PMA) in the United States, currently targeted for 2028 3.
Given the 6-month post-implant follow-up of patients, CARMAT expects completing the EFICAS study (primary endpoint) early November 2025, which will be followed by the publication of its results.
Approval obtained from French authorities for 21 additional Aeson® implants - and filing for reimbursement in France planned early 2026
As a reminder, the EFICAS study is partially funded by the French State (€13 million for 52 implants 4), through the 'Forfait Innovation' program.
In order to allow patients in France to continue benefitting from Aeson® artificial heart after the completion of the 52 implants in the EFICAS study, the French authorities 5 have approved 21 additional implants, under financial terms equivalent to those of the 'Forfait Innovation.
In parallel, CARMAT is taking all necessary steps to be in position to submit a reimbursement application (so-called 'LPPR') for Aeson® at the beginning of 2026, which could allow Aeson® to be covered by the French Social Security system during the same year.
Disclaimer
This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country.
This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT (www.carmatsa.com/en/) and the AMF (www.amf-france.org).
Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today.
Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
City Electric Supply (CES) Launches 2025 Brighter Future Scholarship: Now Accepting Applications
CES is awarding $2,000 and a Milwaukee® Tool starter kit to 10 future electricians across North America to help jumpstart their careers. DALLAS, May 29, 2025 /PRNewswire-PRWeb/ -- City Electric Supply (CES) is now accepting applications for the 2025 Brighter Future Scholarship. CES Cares, the social impact division of CES, launched the program to support the next generation of skilled professionals in the electrical industry. Ten winners across North America will each receive $2,000 and a Milwaukee® Tool starter tool kit to help kickstart their careers. To qualify, applicants must be planning to attend a trade school or complete a certification program. A panel of industry professionals will select the winners. "We're proud to help the next generation of electricians with the resources they need to succeed," said CES Cares Social Impact Manager Karen Gray. "The CES Brighter Future Scholarship helps make it easier for students pursuing careers in the trades — covering part of their education costs and providing tools they need to get started." And it's a promising time to join the industry. Demand for skilled electricians is rising. According to Global Market Insights, the U.S. electrical services market reached $163.9 billion in 2024 and is projected to grow 6.3% annually through 2034. The U.S. Bureau of Labor Statistics also forecasts an 11% growth in employment for electricians from 2023 to 2033 — making it one of the fastest-growing careers. In Canada, Electricity Human Resources Canada (EHRC) estimates the country will need about 28,000 new electricians and electrical contractors by 2028, representing roughly 25% of the current workforce in the sector. With opportunities growing across North America, the Brighter Future Scholarship is one way CES is helping future electricians take the first step. How to apply: Applicants must select a trade school or certificate program and submit an essay explaining why they chose this career path and where they see themselves in the future. To learn more and apply, visit for U.S. applicants and for Canadian applicants. The deadline to apply is June 30, 2025. Winners will be selected in early August. About City Electric Supply (CES) City Electric Supply (CES) is a third-generation family-owned company and one of the top 10 electrical wholesale distributors in North America. We've built lasting trust with industry professionals by empowering local decision-makers, delivering personalized service, and always going the extra mile. With over 5,400 team members and a strong branch network of more than 700 locations, CES supplies the products customers need, when they need them - so businesses can grow with CES by their side. About CES Cares CES Cares, the social impact division of City Electric Supply, is how we give back. Created in 2016, CES Cares brings together all of our charitable and volunteer efforts under one mission: to support those who need it most in the communities we serve. So far, we've raised over $12 million to help children, veterans, people experiencing homelessness, the future of the trades, and more. CES Cares inspires our teams to make a difference - one act of kindness, one community, one day at a time. Media Contact Janan Buisier, City Electric Supply, 214-462-7052, View original content: SOURCE City Electric Supply
Yahoo
34 minutes ago
- Yahoo
Macron's Indonesia trip exposes the worst part of visiting Jakarta
French President Emmanuel Macron came to Jakarta hoping to charm Indonesians with selfies and sweet words. Instead, he got a flood of emotional tweets - and not the endearing kind. His motorcade rolled into the Indonesian capital on Wednesday afternoon, right in time for rush hour. By evening, Jakarta's roads were jammed, tempers were flaring, and netizens were storming social media to let him know exactly how they felt. Macron posted a cheerful selfie with some Indonesian students, writing on X (formerly Twitter), "Indonesia loves France — and the feeling is mutual!" But the comments section quickly turned into a digital traffic jam of its own. "You caused HOURS of traffic!" one user complained. Another added, "Your visit to our country caused a catastrophic congestion last night. Hope you have a nightmare while visiting here." And a third put it plainly: 'Nah, we hate you Macron.' Videos of gridlock on Jakarta's main roads went viral. One clip showed a nightmare along Sudirman, the city's main business strip, with cars barely moving — except, of course, for a squeaky-clean lane reserved for the presidential convoy. To be fair, Jakarta isn't exactly famous for smooth rides. With over 11 million residents and a car-obsessed culture, traffic is a daily battle. But Macron's visit lit the match on a powder keg of public frustration. Local police rushed to clear things up. 'It wasn't Macron,' said traffic director Komarudin. He insisted the gridlock was due to the usual midweek spike in vehicles and not because of the French leader's movements. Still, he admitted the roads were cleared 'just for a moment' while Macron's convoy passed. And in a twist that prompted mockery from some online, even Macron himself reportedly got stuck in Jakarta's traffic. So did his wife, who was delayed returning from a museum visit. Jakarta is among the world's most congested cities and in addition to having more than 11 million residents, there are millions more who commute in from nearby areas. Indonesia has 17,500 islands - and with them many reasons not to stay in the dense and smog-ridden capital. Most travellers to Indonesia want to quickly escape one of the world's most congested cities, and will only briefly see the sprawling city's traffic-choked streets while on their way to island beaches and volcanoes. The belching fumes from heavy traffic have long meant the wearing of face coverings by some of the tens of thousands of motorcyclists clogging the streets at rush hour. Research has shown the continuing impact of air pollution in Asia makes it a bigger global health challenge than alcohol, cigarettes, dirty drinking water or traffic accidents. Indonesia is Southeast Asia's largest economy and has been investing in infrastructure development to boost growth and connectivity. However Jakarta's traffic remains notoriously bad and many arrivals will quickly leave the capital's poor air quality behind for a train trip to Bali via Java and from there to the snorkelling haven of Lombok or to Komodo National Park. The government is even building a new capital, Nusantara, in the Kalimantan region on the island of Borneo, since Jakarta, with its smog and traffic chaos, is no longer viable as a capital in the long term. In addition, the city is falling victim to frequent flooding.
Yahoo
35 minutes ago
- Yahoo
Materion Expands Semiconductor Footprint and Capabilities in Asia Through Key Acquisition
MAYFIELD HEIGHTS, Ohio, May 29, 2025--(BUSINESS WIRE)--Materion (NYSE: MTRN) announced today that it has agreed to purchase manufacturing assets for tantalum solutions in Dangjin City, South Korea, from Konasol, a Korean manufacturer serving the semiconductor and adjacent markets. This strategic investment expands Materion's global footprint with a facility in Asia to better serve semiconductor customers in that region. The transaction includes a newly constructed, state-of-the-art facility with specialized equipment used to produce fully finished tantalum sputtering targets. This acquisition strengthens Materion's position as a leading supplier of tantalum targets, increasing capacity to supply high growth critical deposition materials used in leading-edge semiconductor chips, including those used in high-performance computing and artificial intelligence applications. "Materion has been a strategic partner to the global semiconductor industry for nearly four decades," said Jugal Vijayvargiya, President and Chief Executive Officer. "The acquisition strengthens our footprint in Asia to support and service global Tier I semiconductor customers and expands our position as a leading global supplier of deposition materials." The transaction is subject to regulatory review and is expected to close within 90 days. Please refer to our investor presentation at for more information. About Materion Materion Corporation is a global leader in advanced materials solutions for high-performance industries including semiconductor, industrial, aerospace & defense, energy and automotive. With nearly 100 years of expertise in specialty engineered alloy systems, inorganic chemicals and powders, precious and non-precious metals, beryllium and beryllium composites, and precision filters and optical coatings, Materion partners with customers to enable breakthrough solutions that move the world forward. Headquartered in Mayfield Heights, Ohio, the company employs more than 3,000 people worldwide, serving customers in more than 60 countries. View source version on Contacts FOR FURTHER INFORMATION, PLEASE CONTACT: MediaScott Tennant(216) InvestorsKyle Kelleher(216) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
